Anders Österborg's Group
Our group, which is lead by prof Anders Österborg and prof Håkan Mellstedt, has a tradition since the early 1980ies in developing targeted therapies for patients with B cell malignancies (chronic lymphocytic leukemia and B cell lymphomas).
The aim is to develop and optimize chemotherapy-free precision medicine to avoid or delay multidrug resistance and to reduce long-term conventional toxicity. Our research is conducted in 4 separate areas, each lead by a senior project leader and group member.
Research area A: Exploring new targets and developing new drugs.
Lead by Mohammad Hojjat-Farsangi (PhD, senior researcher).
We have a current focus on ROR1, an embryonic antigen expressed by many tumor types but abundant on most normal cells. Extensive biological characterization of ROR1 (expression pattern, signaling) is performed and a first-in-class small molecule inhibitor of ROR1 has been develop in collaboration with Kancera AB (Solna Science Park) and is currently undergoing preclinical testing. Example of publication: Hojjat-Farsangi M et al, Leukemia 2018).
Research area B: Immune regulation of B cell malignancies.
Lead by Marzia Palma (MD, PhD)
We perform in-depth analysis of immunoregulatory cell populations preferentially in patients with CLL and Hodgkin’s disease. An important part is monitoring of immune functions during targeted therapies such as BTK-inhibitors (ibrutinib, zanubrutinib) and during Bcl-2 inhibition (venetoclax) in patients. Example of publication: Palma M et al, Br J Haematologica 2018.
Research area C: Academic clinical trials using targeted precision therapeutics in B cell malignancies.
Lead by: Jeanette Lundin, assoc. prof.
The aim to develop optimized chemotherapy-free treatment regimens, including but not limited to BTK and Bcl-2 inhibitors. An important project is the ongoing ibrutinib “On-Off” study, with the aim to reduce the risk of acquired resistance (BTK-mutation) and long-term side effects. Example of publication: Winqvist M et al, Br J Haematol 2018.
Research area D: Real-world studies on new precision therapies in CLL and NHL.
Lead by: Lotta Hansson, assoc.prof.
Here we aim to describe the true effects of new (high-cost) targeted therapeutics in a wider population of patients treated real-World i.e. outside clinical trials that often recruit selected patients. Real-World evidence is of major importance for patients, health care professionals ans society as a whole. Example of publications: Winqvist M et al, Haematologica 2019; Eketorp Sylvan S et al, Haematologica 2019
Group members spring 2020:
Asklid Anna, MD, PhD student
Burén Gunilla, Head Secretary
Eketorp Sylvan Sandra, PhD, Specialist Doctor
Fahlén Anna, Research Nurse
Frödin Jan-Erik, Associate Professor, Chief Physician
Ghaderi Amineh, PhD student
Hansson Lotta, Associate Professor, Chief Physician
Heimersson Kia, Biomedical Scientist
Hojjat-Farsangi Mohammad, PhD, Senior Researcher
Jeddi-Tehrani Mahmood, PhD, Senior Researcher
Karlsson Claes, PhD, Chief Physician
Kokhaei Parviz, PhD, Senior Researcher
Lundin Jeanette, Associate Professor, Chief Physician
Mattsson Agnes, PhD student, Specialist Doctor
Mellstedt Håkan, Professor, Chief Physician
Mosfegh Ali, PhD, Senior Researcher
Mulder Tom, MD, PhD student
Okhovat Mohammad, Master student
Palma Marzia, PhD, Assistant Chief Physician
Relander Leila, Research Coordinator
Svensson Ann, Biomedical Scientist
Winqvist Maria, PhD student, Specialist Doctor
Österborg Anders, Professor, Chief Physician